MIRROR

AMGEN PRESENTS NEW DATA THAT SHOW BLOOD PRESSURE DECREASES FOR ADULTS TREATED WITH KRYSTEXXA® (PEGLOTICASE)

Retrieved on: 
Thursday, November 2, 2023

The data will be presented at the American Society of Nephrology Kidney Week, taking place Nov. 2-5, in Philadelphia.

Key Points: 
  • The data will be presented at the American Society of Nephrology Kidney Week, taking place Nov. 2-5, in Philadelphia.
  • "Recognizing the high prevalence of hypertension among these patients, we're excited to present data that offers new insight into the potential role of urate reduction with KRYSTEXXA with methotrexate in regulating blood pressure."
  • Treatment groups had similar blood pressure prior to treatment.
  • "These new data add to prior studies and further support the potential role that both KRYSTEXXA urate-lowering and methotrexate administration played in the blood pressure changes observed."

InventHelp Inventor Develops New Rain Deflector for Trucks (FLA-3439)

Retrieved on: 
Tuesday, October 17, 2023

My design would greatly improve visibility when traveling in the rain."

Key Points: 
  • My design would greatly improve visibility when traveling in the rain."
  • The patent-pending invention provides a cover over and around the mirror to prevent rain, snow, sleet, etc.
  • The cover would extend out to where it would repel moisture from accumulating on the windows while driving.
  • 21-FLA-3439, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext.

Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection With Methotrexate Published in ACR Open Rheumatology

Retrieved on: 
Thursday, July 6, 2023

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of the long-term data from the MIRROR randomized controlled clinical trial of KRYSTEXXA® (pegloticase) injection with methotrexate, a commonly used immunomodulator, in ACR Open Rheumatology [ https://doi.org/10.1002/acr2.11578 ].

Key Points: 
  • Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of the long-term data from the MIRROR randomized controlled clinical trial of KRYSTEXXA® (pegloticase) injection with methotrexate, a commonly used immunomodulator, in ACR Open Rheumatology [ https://doi.org/10.1002/acr2.11578 ].
  • “Encouragingly, urate-lowering efficacy with the co-therapy approach was sustained over time with continued treatment in most patients.
  • The improvement in both groups was clinically meaningful (meaningful clinically important difference [MCID]: −0.22) but was not significantly different between groups (difference: −0.04 [−0.21, 0.13], p=0.6287).
  • Patients with questions can speak to a Gout Nurse Advocate at 833-469-4688.

Leading Disability Experts and Tech Innovators Announce “Advocate” - A Groundbreaking Platform That Leverages AI to Make Applying for Social Security and Veterans Disability Faster, Easier and More Accessible for Over 80 Million Eligible Americans

Retrieved on: 
Friday, June 2, 2023

The financing round was led by Lerer Hippeau and included an investment by Khosla Ventures.

Key Points: 
  • The financing round was led by Lerer Hippeau and included an investment by Khosla Ventures.
  • The government disability benefits system is cumbersome, outdated and frustratingly difficult to navigate,” said Emilie Poteat PhD, the founder and CEO of Advocate.
  • ”We employ the latest technological and algorithmic advancements to simplify this process and help both recipients and government staff alike.
  • Our portfolio includes more than 400 leading enterprise and consumer businesses including Guideline, MIRROR, Blockdaemon, K Health, Allbirds, ZenBusiness, and Thrive.

New Analyses of the MIRROR Randomized Controlled Trial in Uncontrolled Gout Presented at the 2023 EULAR European Congress of Rheumatology

Retrieved on: 
Wednesday, May 31, 2023

Presentations are part of expert discussions at the EULAR European Congress of Rheumatology , May 31 - June 3, 2023, in Milan.

Key Points: 
  • Presentations are part of expert discussions at the EULAR European Congress of Rheumatology , May 31 - June 3, 2023, in Milan.
  • Data presented from Horizon’s MIRROR randomized controlled trial (RCT), which evaluated KRYSTEXXA in combination with methotrexate for uncontrolled gout, provide further evidence of the impact of therapy on patient-reported outcomes (PROs), urate depletion and bone remodeling.
  • “Uncontrolled gout is far more painful and dangerous than most people know,” said Brian LaMoreaux, M.D., M.S., senior medical director, Horizon.
  • Bone erosion remodeling after depletion of monosodium urate deposition with intensive urate-lowering with pegloticase in patients with uncontrolled gout: MIRROR RCT dual-energy CT findings (POS0514)

Horizon Therapeutics plc Announces Presentation of Data that Advances the Understanding of Rheumatic Diseases at the 2023 EULAR European Congress of Rheumatology

Retrieved on: 
Tuesday, May 23, 2023

Horizon Therapeutics plc (Nasdaq: HZNP) today announced plans for the first presentation of data from a Phase 2 study of dazodalibep, the company’s investigational therapy for Sjögren’s syndrome, during the 2023 EULAR European Congress of Rheumatology , May 31 - June 3, 2023, in Milan.

Key Points: 
  • Horizon Therapeutics plc (Nasdaq: HZNP) today announced plans for the first presentation of data from a Phase 2 study of dazodalibep, the company’s investigational therapy for Sjögren’s syndrome, during the 2023 EULAR European Congress of Rheumatology , May 31 - June 3, 2023, in Milan.
  • The company will also present additional data on KRYSTEXXA® (pegloticase) injection, including new analyses from the MIRROR randomized clinical trial.
  • “Our pipeline continues to strengthen as we work to address challenging research questions and bring new thinking that can advance standards for patient care in the rheumatology field,” said Elizabeth H.Z.
  • Thompson, Ph.D., executive vice president, research and development, Horizon.

lululemon athletica inc. Announces Fourth Quarter and Full Year Fiscal 2022 Results

Retrieved on: 
Tuesday, March 28, 2023

lululemon athletica inc. (NASDAQ:LULU) today announced financial results for the fourth quarter and fiscal year ended January 29, 2023.

Key Points: 
  • lululemon athletica inc. (NASDAQ:LULU) today announced financial results for the fourth quarter and fiscal year ended January 29, 2023.
  • The effective income tax rate for the fourth quarter of 2022 was 62.3% compared to 26.4% for the fourth quarter of 2021.
  • The adjusted effective tax rate was 28.7% for the fourth quarter of 2022 compared to 26.4% for the fourth quarter of 2021.
  • Adjusted diluted earnings per share for the fourth quarter of 2022 were $4.40 compared to $3.37 in the fourth quarter of 2021.

Over 7,300 industry talents at HKTDC FILMART and EntertainmentPulse

Retrieved on: 
Thursday, March 16, 2023

FILMART and EntertainmentPulse brought together over 7,300 industry talents from 41 countries and regions.

Key Points: 
  • FILMART and EntertainmentPulse brought together over 7,300 industry talents from 41 countries and regions.
  • Industry leaders participated in EntertainmentPulse conference series to talk about the latest entertainment industry trends.
  • EntertainmentPulse, the concurrent conference series of FILMART, featured a dedicated session on Web3 in the entertainment industry.
  • Users can revisit all the exciting content from EntertainmentPulse and utilise the direct messaging function offered through the FILMART online platform.

Littlebird Connected Care Announces Ex-MIRROR Executive Kristie D'Ambrosio-Correll Joining as Chief Technology Officer and Co-founder

Retrieved on: 
Tuesday, January 17, 2023

SEATTLE, Jan. 17, 2023 /PRNewswire/ -- Little bird Connected Care, Inc., announced today that Kristie D'Ambrosio-Correll, former executive at MIRROR, will join the company as its Chief Technology Officer. D'Ambrosio-Correll ran engineering, product, manufacturing and supply chain through the Lululemon Corporation's $500 million acquisition of MIRROR until January of this year. D'Ambrosio-Correll will also become Littlebird Co-founder alongside Founder and Chief Executive Officer Monica Plath who started the company in Spring 2020.

Key Points: 
  • SEATTLE, Jan. 17, 2023 /PRNewswire/ -- Little bird Connected Care, Inc., announced today that Kristie D'Ambrosio-Correll, former executive at MIRROR, will join the company as its Chief Technology Officer.
  • D'Ambrosio-Correll will also become Littlebird Co-founder alongside Founder and Chief Executive Officer Monica Plath who started the company in Spring 2020.
  • The company received a patent for its Bluetooth Chain of Custody "Connected Care Tether" technology January 3rd, 2023.
  • Pre-Seed Littlebird is a 2x award-winning, patented Toddler wearable + Connected Care ecosystem, the last remaining biometric greenspace.

Recast raises $3.4 million for automated marketing data science platform

Retrieved on: 
Thursday, December 15, 2022

Recast puts state-of-the-art marketing science tools into the hands of practitioners.

Key Points: 
  • Recast puts state-of-the-art marketing science tools into the hands of practitioners.
  • Tools for marketing mix modeling (MMM), forecasting and planning, and robust marketing optimization can be used directly by marketing teams without having to wait on data scientists or outside consulting firms.
  • Recast plans to use the investment to scale the software engineering and data science teams to increase their lead as the best automated marketing science platform in the world.
  • Recast is an automated marketing data science platform providing the next generation of marketers with near-real-time marketing mix modeling and sophisticated forecasting and planning tools.